title: Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia.
abstract: Anemia in heart failure is related to advanced New York Heart Association classes, severe systolic dysfunction, and reduced exercise tolerance. Although anemia is frequently found in congestive heart failure (CHF), little is known about the effect of its' correction with erythropoietin (EPO) on cardiac structure and function. The present study examines, in patients with advanced CHF and anemia, the effects of beta-EPO on left ventricular volumes, left ventricular ejection fraction (LVEF), left and right longitudinal function mitral anular plane systolic excursion (MAPSE), tricuspid anular plane excursion (TAPSE), and pulmonary artery pressures in 58 patients during 1-year follow-up in a double-blind controlled study of correction of anemia with subcutaneous beta-EPO. Echocardiographic evaluation, B-Type natriuretic peptide (BNP) levels, and hematological parameters are reported at 4 and 12 months. The patients in group A after 4 months of follow-up period demonstrated an increase in LVEF and MAPSE (P < 0.05 and P < 0.01, respectively) with left ventricular systolic volume reduction (P < 0.02) with respect to baseline and controls. After 12 months, results regarding left ventricular systolic volume LVEF and MAPSE persisted (P < 0.001). In addition, TAPSE increased and pulmonary artery pressures fell significantly in group A (P < 0.01). All these changes occurred together with a significant BNP reduction and significant hemoglobin increase in the treated group. Therefore, we revealed a reduced hospitalization rate in treated patients with respect to the controls (25% in treated vs. 54% in controls). In patients with anemia and CHF, correction of anemia with beta-EPO and oral iron over 1 year leads to an improvement in left and right ventricular systolic function by reducing cardiac remodeling, BNP levels, and hospitalization rate.
authors.affiliation: Department of Internal Medicine and Metabolic Diseases, Cardiology Section, Le Scotte Hospital, University of Siena, Siena, Italy. palazzuoli2@unisi.it
authors.forename: Alberto
authors.initials: A
authors.lastname: Palazzuoli
authors.forename: Donald S
authors.initials: DS
authors.lastname: Silverberg
authors.forename: Anna
authors.initials: A
authors.lastname: Calabrò
authors.forename: Tommaso
authors.initials: T
authors.lastname: Spinelli
authors.forename: Ilaria
authors.initials: I
authors.lastname: Quatrini
authors.forename: Maria S
authors.initials: MS
authors.lastname: Campagna
authors.forename: Beatrice
authors.initials: B
authors.lastname: Franci
authors.forename: Ranuccio
authors.initials: R
authors.lastname: Nuti
mesh_terms: D000740:Anemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000627:therapeutic use*; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D006333:Heart Failure / Q000150:complications / Q000503:physiopathology*; D006397:Hematinics / Q000627:therapeutic use*; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007279:Injections, Subcutaneous; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011651:Pulmonary Artery / Q000187:drug effects* / Q000503:physiopathology; D011994:Recombinant Proteins; D018487:Ventricular Dysfunction, Left / Q000150:complications / Q000503:physiopathology*; D018497:Ventricular Dysfunction, Right / Q000150:complications / Q000503:physiopathology*; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D005296:Ferrous Compounds; D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D020097:Natriuretic Peptide, Brain; C011819:ferrous gluconate